Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Metabolic Disorders

Set Alert for Metabolic Disorders

10 Clinical Trials To Watch Out For In 2023

Scrip surveys the Phase III clinical trial readout landscape and picks 10 of the more interesting studies set to report in 2023, with a few added extras. AstraZeneca, Novo Nordisk, Novartis and Roche feature heavily.

Scrip Perspectives Clinical Trials

Five-Plus-Five Equals A Focus On Execution At Lilly In 2023

Executives told Scrip the company is ready to move five programs into Phase III and launch five products this year, including an obesity indication for Mounjaro, but one drug has since received a CRL.

Launches Strategy

Oramed Failure Highlights Insurmountable Challenge Of Oral Insulin Delivery

Oramed's attempts to advance an oral formulation of insulin for type 2 diabetes patients have been scuppered with a Phase III fail that has sunk the stock.

Metabolic Disorders Clinical Trials

Stock Watch: Tales Of Stock Price Overreactions

Two clinical trial announcements in the same NASH indication separated by almost nine years had very similar stock price reactions despite the known unknowns of NASH remaining unknown.

Stock Watch Companies

Sidestepping Gene Therapy ‘Land Grab’ Mistakes, Rocket Is Set For First Filings In 2023

While other gene therapy companies faced major clinical and financing problems in 2022, Rocket Pharma sidestepped some of these pitfalls and is gearing up for two US filings this year.

Metabolic Disorders Cardiovascular

The Top Five Pharma Stories Of 2022

Scrip has taken a look back at five of the biggest story themes in no particular order of 2022 where once again the biopharma industry had plenty on its plate.

Scrip Perspectives M & A

Potential Milestone Year Ahead For Korean NASH Contenders

Scrip takes a look at key recent drug development activities in the NASH area by Korean firms, which are now pursuing the global development of their candidates as they look to leverage innovation to expand internationally.

South Korea Liver & Hepatic

Sosei Heptares Adds Lilly To Big Pharma Client List

The Japan-UK group is ending the year on a high, banking $37m upfront from a pact with Eli Lilly that will focus on finding small molecules which modulate G protein-coupled receptor (GPCR) targets.

Metabolic Disorders Deals

Lilly Revenue Guidance Rises Along With Diabetes, Obesity Investments

Lilly will increase spending, resulting in lower-than-expected EPS, to drive its revenue growth, relying on sales of new products, particularly its next generation of incretin agonists for diabetes and obesity.

Growth Business Strategies

Novo Nordisk Named And Shamed For Paying Pharmacists To Boost Weight Loss Drug Sales

The company has been publicly reprimanded for its training program for UK pharmacists, which the industry watchdog judged to be solely focused on increasing use of weight loss drug Saxenda

Companies Commercial

Avrobio Plots Comeback With Early Data From Gaucher’s Gene Therapy

Early data in Gaucher disease suggest Avrobio’s hematopoietic stem cell gene therapy could help patients who do not response to enzyme replacement therapy.

Commercial Companies

Lessons From Novo Nordisk’s Mads Øvlisen, The Father Of CSR

When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.

Outlook 2023 Leadership
See All
UsernamePublicRestriction

Register